Asked by: Karin Smyth (Labour - Bristol South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many nurses have worked in NHS community health services on average in each of the last 10 years.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
NHS England publishes Hospital and Community Health Services workforce statistics for England. These include staff working for hospital trusts and integrated care boards, but excludes staff working for other providers such as in primary care, general practice or social care. This data is drawn from the Electronic Staff Record, the human resources system for the National Health Service.
The latest statistics on NHS nursing workforce by area of nursing and care setting can be found in the link below within the ‘Nurses by Setting’ worksheet:
Within this data there are nurses working in community settings within several staff groups including community health nurses, community learning disability nurses, community mental health nurses, and as health visitors.
Asked by: Jim Shannon (Democratic Unionist Party - Strangford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if she will have discussions with NHS England on the effectiveness of its Commercial Framework in tackling challenges presented by the appraisal and reimbursement system when applied to combination medicines and medicines with multiple indications.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
As part of the 2024 voluntary scheme for branded medicines pricing, access, and growth, NHS England has committed to undertake two consultations on its Commercial Framework for New Medicines. The first of these will be launched in summer 2024 and will align with the Competition and Markets Authority’s (CMA) statement on combination medicines. In addition, it will be more explicit about the approach taken for assessing the eligibility of medicines treating multiple indications to qualify for indication specific pricing mechanisms.
Following the first consultation, a revised framework will be published by the end of 2024, and engagement with pharmaceutical companies and patient groups on these issues is already taking place.
Asked by: Tanmanjeet Singh Dhesi (Labour - Slough)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps she is taking to ensure (a) transparency and (b) parental consent in clinical trials involving children.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
There are legal measures in place to ensure informed consent in clinical trials, through the Medicines for Human Use (Clinical Trials) Regulations 2004. Parental consent for clinical trials investigating medicines which involve children is also legislated for via the same Regulations.
Promoting and ensuring transparency is central to the role of the Health Research Authority to facilitate safe and ethical research as defined in the Care Act 2014. This includes clinical trials involving children.
Asked by: Tanmanjeet Singh Dhesi (Labour - Slough)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what measures are in place to ensure informed consent in clinical trials.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
There are legal measures in place to ensure informed consent in clinical trials, through the Medicines for Human Use (Clinical Trials) Regulations 2004. Parental consent for clinical trials investigating medicines which involve children is also legislated for via the same Regulations.
Promoting and ensuring transparency is central to the role of the Health Research Authority to facilitate safe and ethical research as defined in the Care Act 2014. This includes clinical trials involving children.
Asked by: Jim Shannon (Democratic Unionist Party - Strangford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 7 March 2024 to Question 15636 on Blood Cancer: Drugs, on what date her Department first became aware of challenges presented by the appraisal of combination therapies; and what solutions her Department is considering with NHS England to ensure continued equal access to combination medicines for multiple myeloma across the UK.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
NHS England, the National Institute for Health and Care Excellence (NICE), and the Association of the British Pharmaceutical Industry (ABPI) worked closely with the Competition and Markets Authority (CMA) over a number of years on the CMA’s statement on combination therapies, published in November 2023.
The steps taken by the CMA provide a clear commercial position that means that deals involving multiple drugs licensed by different companies can now be agreed under specific circumstances. This has been welcomed by the ABPI as an opportunity to unlock the door to more transformative combination therapies on the National Health Service.
Asked by: John Hayes (Conservative - South Holland and The Deepings)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether she will make an assessment of the potential merits of taking legislative steps to stop private clinics prescribing puberty-blockers to children.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
Following the publication of Dr Cass’ Final Report, my Rt hon. Friend, the Secretary of State for Health and Social Care has made a commitment to look closely at what can be done to curtail any loopholes in prescribing practices for children with gender dysphoria, including legislative options.
The Care Quality Commission will expect registered providers to take into account the recommendations of the Cass Review. If a private organisation registered with the Care Quality Commission fails to meet the conditions of its registration, then the regulator can take enforcement action.
Asked by: Julian Sturdy (Conservative - York Outer)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps she is taking to ensure that there are sufficient numbers of Parkinson’s specialist nurses.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
Under the NHS Long Term Workforce Plan, backed by more than £2.4 billion over the next five years, the National Health Service will focus on expanding the number of clinicians, including nurses, who train to take up enhanced and advanced roles, and work as part of multidisciplinary teams with the right skills to meet the changing needs of patients. The ambition is to train at least 3,000 advanced practitioners in 2024 and 2025 across all specialties, and to increase the number in training to 5,000 a year by 2029. The Long Term Workforce Plan also sets out actions and reforms needed to improve workforce supply and retention.
Asked by: Julian Sturdy (Conservative - York Outer)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps she is taking to ensure that Parkinson’s specialist nurses are retained in the profession.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
Under the NHS Long Term Workforce Plan, backed by more than £2.4 billion over the next five years, the National Health Service will focus on expanding the number of clinicians, including nurses, who train to take up enhanced and advanced roles, and work as part of multidisciplinary teams with the right skills to meet the changing needs of patients. The ambition is to train at least 3,000 advanced practitioners in 2024 and 2025 across all specialties, and to increase the number in training to 5,000 a year by 2029. The Long Term Workforce Plan also sets out actions and reforms needed to improve workforce supply and retention.
Asked by: Rachael Maskell (Labour (Co-op) - York Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent assessment she has made of the effectiveness of the BALM programme.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
NHS England is currently undertaking a review of how health and wellbeing support could be delivered more effectively. As part of this review, the team will: assess NHS England’s current contracts; work with integrated care boards, National Health Service trusts, and primary care organisations to understand the scale and impact of locally provided provision; and work with system partners and stakeholders including royal colleges, the voluntary sector, and the independent sector to understand how demand for these services has changed over recent years.
Asked by: John Hayes (Conservative - South Holland and The Deepings)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how much funding her Department has given to Stonewall since 2019.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
Our financial records show a total sum of £6,000 paid to Stonewall between the years 2019 to 2020, as part of the Diversity Champions annual membership. This is broken down into £3,000 between 1 January 2019 and 31 December 2019, and £3,000 between 1 January 2020 and 31 December 2020. As of February 2021, the Department’s membership with Stonewall lapsed, with no further payments made from 2021 to date.